Emory University, Winship Cancer Institute, Atlanta, Georgia, USA.
Curr Opin Oncol. 2010 Mar;22(2):79-85. doi: 10.1097/CCO.0b013e328335a583.
Angiogenesis is critical for tumor growth and progression. Strategies to inhibit angiogenesis have gained a strong foothold for the treatment of a variety of malignancies. This review will provide the relevant interventions targeted against specific angiogenesis pathways with or without known effective therapies for nonsmall cell lung cancer (NSCLC).
Bevacizumab, a mAb against the vascular endothelial growth factor, has been approved by the U.S. Food and Drug Administration for the treatment of patients with advanced stage nonsquamous NSCLC in combination with the carboplatin-paclitaxel regimen. This has prompted the evaluation of a variety of novel agents for the treatment of NSCLC. Agents that inhibit the vascular endothelial growth factor receptor tyrosine kinase are currently under extensive investigation, but the initial results with combination strategies have not been encouraging. Identification of predictive biomarkers for antiangiogenic agents continues to be elusive and remains a major focus of ongoing research. Apart from vascular endothelial growth factor, other targets within the angiogenic pathway are also being evaluated in the clinical setting.
In this article, we review the recent data with antiangiogenic agents in NSCLC and their implications for clinical use and future research.
血管生成对于肿瘤的生长和进展至关重要。抑制血管生成的策略已在多种恶性肿瘤的治疗中得到了广泛应用。本文将对针对特定血管生成途径的相关干预措施进行综述，这些途径既有已知的非小细胞肺癌（NSCLC）的有效治疗方法，也有尚无有效治疗方法的途径。
贝伐单抗是一种针对血管内皮生长因子的单克隆抗体，已被美国食品和药物管理局批准与卡铂紫杉醇联合用于治疗晚期非鳞状 NSCLC 患者。这促使人们对多种新型药物进行了 NSCLC 的治疗评估。目前正在广泛研究抑制血管内皮生长因子受体酪氨酸激酶的药物，但联合治疗策略的初步结果并不令人鼓舞。识别抗血管生成药物的预测生物标志物仍然难以捉摸，这仍然是正在进行的研究的主要重点。除了血管内皮生长因子之外，血管生成途径中的其他靶点也正在临床环境中进行评估。
本文综述了 NSCLC 中抗血管生成药物的最新数据及其对临床应用和未来研究的意义。
